Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.82 |
| ▸ | NPC1 | O15118 | 6/20 | 0.82 |
| ▸ | RAB9A | P51151 | 6/20 | 0.82 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.82 |
| ▸ | MEN1 | O00255 | 2/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | GAA | P10253 | 3/20 | 0.66 |
| ▸ | LMNA | P02545 | 3/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.65 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.48 |
| ▸ | RELA | Q04206 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 3/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12206687 | 0.88 | MAPT (0.66) | MAPTNPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL16781516 | 0.85 | MAPT (0.64) | MAPTNPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL16781515 | 0.85 | MAPT (0.83) | MAPTNPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL18470712 | 0.85 | MAPT (0.84) | MAPTNPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL12206695 | 0.81 | MAPT (0.75) | MAPTNPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL2524831 | 0.80 | MAPT (1.00) | MAPTNPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL12206705 | 0.79 | MAPT (1.00) | MAPTNPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL12206704 | 0.79 | MAPT (0.78) | MAPTNPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL12206696 | 0.78 | MAPT (0.77) | MAPTNPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL13170636 | 0.77 | MAPT (0.93) | MAPTNPC1RAB9AKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170037039-A1 | RETINOIC ACID RECEPTOR ANTAGONISTS AS CHAPERONE-MEDIATED AUTHOPHAGY MODULATORS AND USES THEREOF | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. (US) | 2017-02-09 | — | — | US | disclosed |
| US-9512092-B2 | Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20150166492-A1 | RETINOIC ACID RECEPTOR ANTAGONISTS AS CHAPERONE-MEDIATED AUTOPHAGY MODULATORS AND USES THEREOF | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2015-06-18 | — | — | US | disclosed |
| US-8581005-B2 | Mitochondrial inhibitors to treat human disease | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2013-11-12 | — | — | US | disclosed |
| US-8581005-B2 | Mitochondrial inhibitors to treat human disease | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2013-11-12 | — | — | US | disclosed |
| US-20120093728-A1 | MITOCHONDRIAL INHIBITORS TO TREAT HUMAN DISEASE | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. | 2012-04-19 | — | — | US | disclosed |
| US-20120093728-A1 | MITOCHONDRIAL INHIBITORS TO TREAT HUMAN DISEASE | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. | 2012-04-19 | — | — | US | disclosed |
| US-20110251189-A1 | HYPOXIA TARGETED COMPOUNDS FOR CANCER DIAGNOSIS AND THERAPY | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2011-10-13 | — | — | US | disclosed |
| US-20110251189-A1 | HYPOXIA TARGETED COMPOUNDS FOR CANCER DIAGNOSIS AND THERAPY | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2011-10-13 | — | — | US | disclosed |
| WO-2010120337-A1 | MITOCHONDRIAL INHIBITORS TO TREAT HUMAN DISEASE | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010068238-A1 | HYPOXIA TARGETED COMPOUNDS FOR CANCER DIAGNOSIS AND THERAPY | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120093728-A1 | MITOCHONDRIAL INHIBITORS TO TREAT HUMAN DISEASE | TFAM, AIFM1, FH | MAPT 1206/4885NPC1 616/4885RAB9A 985/4885 |
| US-20170037039-A1 | RETINOIC ACID RECEPTOR ANTAGONISTS AS CHAPERONE-MEDIATED AUTHOPHAGY MODULATORS AND USES THEREOF | RXRA, RARB, RARA | MAPT 1343/4885NPC1 355/4885RAB9A 402/4885 |
| US-20110251189-A1 | HYPOXIA TARGETED COMPOUNDS FOR CANCER DIAGNOSIS AND THERAPY | HIF1A, HIF1AN, HYOU1 | MAPT 3842/4885NPC1 3139/4885RAB9A 4390/4885 |
| US-20150166492-A1 | RETINOIC ACID RECEPTOR ANTAGONISTS AS CHAPERONE-MEDIATED AUTOPHAGY MODULATORS AND USES THEREOF | RARA, RARB, RXRA | MAPT 1742/4885NPC1 277/4885RAB9A 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.